Company NurExone Biologic Inc.

Equities

NRX

CA67059R1091

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 03:39:16 2024-05-17 pm EDT			5-day change	1st Jan Change
0.49 ^CAD	-2.00%		-12.50%	+66.10%

Apr. 25	NurExone Biologic Announces OTCQB Listing And DTC Eligibility	MT
Apr. 02	NurExone Biologic Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.

Number of employees: 12

Managers	Title	Age	Since
Lior Shaltiel CEO	Chief Executive Officer	-	21-03-31
Eran Ovadya DFI	Director of Finance/CFO	-	22-06-14

Members of the board	Title	Age	Since
Jay Richardson BRD	Director/Board Member	78	22-01-02
Gadi Riesenfeld BRD	Director/Board Member	79	23-07-05
Yoram Drucker CHM	Chairman	59	19-12-31
Oded Orgil BRD	Director/Board Member	57	22-06-14
Lior Shaltiel CEO	Chief Executive Officer	-	21-03-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	65,814,822	61,834,822 ( 93.95 %)	0	93.95 %

Name	Equities	%	Valuation
Yoram Drucker 5.836 %	3,230,000	5.836 %	2 M $
Ron Abraham Mayron 1.229 %	680,000	1.229 %	317 560 $
Jay Richardson 0.1265 %	70,000	0.1265 %	32 690 $
Gadi Riesenfeld 0.000000 %	0	0.000000 %	- $
Oded Orgil 0.000000 %	0	0.000000 %	- $
Lior Shaltiel 0.000000 %	0	0.000000 %	- $
Eran Ovadya 0.000000 %	0	0.000000 %	- $

NurExone Biologic, Inc.

9 Mezada Street BSR 3 Tower

5120109, Bnei-Brak

http://www.nurexone.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3601 USD

Average target price

2.907 USD

Spread / Average Target

+707.18%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
NUREXONE BIOLOGIC INC.	+66.10%	23.71M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research